CA Patent

CA2667553A1 — Methods and combination therapies for treating alzheimer's disease

Assigned to Medivation Neurology Inc · Expires 2008-05-02 · 18y expired

What this patent protects

The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable …

USPTO Abstract

The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.

Drugs covered by this patent

Patent Metadata

Patent number
CA2667553A1
Jurisdiction
CA
Classification
Expires
2008-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Medivation Neurology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.